Related Experiment Videos
EVE and beyond, retro and prospective insights
1Division of Cardiovascular Research, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8. mr@sickkids.on.ca
The American Journal of Physiology
|July 17, 1999
Summary
An endogenous vascular elastase (EVE) is key in pulmonary hypertension vascular changes. Targeting fibronectin production mechanisms prevents intimal lesion development.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Pulmonary hypertension involves significant vascular remodeling.
- Endogenous vascular elastase (EVE) has been identified as a key mediator in these vascular changes.
- Serum factors stimulating EVE transcription and associated signaling pathways are under investigation.
Discussion:
- EVE activation involves the mitogen-activated protein kinase pathway and AML1 transcription factor nuclear expression.
- Proteases release ECM-bound growth factors and induce tenascin transcription via beta(3)-integrin.
- Tenascin influences smooth muscle cell morphology and growth factor receptor activation, promoting proliferation.
Key Insights:
- Elastin peptides upregulate fibronectin production, crucial for smooth muscle cell migration.
- Targeting mechanisms of enhanced fibronectin production shows promise in preventing intimal lesions.
- EVE's role in vascular remodeling offers potential therapeutic targets for pulmonary hypertension.
Outlook:
- Further research into EVE's regulatory mechanisms could reveal novel therapeutic strategies.
- Developing inhibitors of EVE or its downstream effectors may halt or reverse vascular pathology.
- Understanding the interplay between ECM components and cellular responses is vital for treating vascular diseases.